A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
NCT07759154
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Attention-deficit/Hyperactivity Disorder
- Emotional Dysregulation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Last updated on ClinicalTrials.gov
- September 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Louisiana · 1
- Nola Research Works · New Orleans, LA
New Jersey · 1
- Center for Emotional Fitness · Cherry Hill, NJ
Oregon · 1
- Summit Research Network · Portland, OR
Texas · 2
- Donald J. Garcia, Jr, MD, PA · Austin, TX
- Houston Clinical Trials LLC · Bellaire, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.